(Q58023728)

English

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

article published in 2013

In more languages

Statements

scholarly article

0 references

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib (English)

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Paul La Rosée

1

0 references

Andreas Hochhaus

object named as

Andreas Hochhaus

9

0 references

Philippe Martiat

2

object named as

Philippe Martiat

0 references

author name string

Armin Leitner

3

0 references

Thomas Klag

4

0 references

Martin C. Müller

5

0 references

Philipp Erben

6

0 references

Thomas Schenk

7

0 references

Susanne Saussele

8

0 references

publication date

28 April 2013

0 references

Annals of Hematology

0 references

92

0 references

10

0 references

1345-1350

0 references

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1769-2

21 January 2018

Identifiers

10.1007/S00277-013-1769-2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58023728&oldid=1928887652"